Zimbabwe is recording increased cases of drug resistant HIV which have contributed to shortages of Abacavier, a drug administered to patients a Senior Government Official said on Wednesday.
Abacavier is administered to patients who would have failed or reacted to initial drug combinations.
The Herald reported that the Secretary for Health and Child Care Gerald Gwinji said that at least 35,000 patients were on Abacavier after failing the first line treatment.
He also said that the drug’s availability was also being impeded by foreign currency shortages.
He also attributed the increase in resistance to the first line treatment to advanced technology which enabled health authorities to identify cases that are not responding.
“As we now monitor closely with new technology such as viral load testing, the issue of resistance and defaulting has suddenly seen a number of patients requiring second line drugs, therefore going beyond the stocks that we normally have,’’ he said.
Meanwhile, the National AIDS Council has introduced night HIV testing.
Harare provincial AIDS coordinator Adonijah Muzondiona, said the programme known as “moonlight testing’’ had been designed for people who could not be tested during the day for various reasons.
“We are trying to make sure that everyone who is HIV positive is tested and immediately put on antiretroviral drugs,’’ he said.
An estimated 1.2 million people are living with HIV in Zimbabwe.
The Joint Admission and Matriculation Board (JAMB), has revealed why some candidates with high scores…
Scores of Nigerians have taken to the X platform to condemn the National Secretary of…
The Police have confirmed the death of two middle-aged men who tragically lost their lives,…
Professor Augustine Angba, the Vice-Chancellor of the University of Cross River State (UNICROSS), has been…
A 300-level Nursing student of Babcock University, Ilishan-Remo, Ogun State, Miss Oluwateniola Omidiji, has demanded…
The spokesperson of the Lagos State Police Command, Benjamin Hundeyin, has warned ‘woke Nigerians’ against…
This website uses cookies.